Patents Assigned to Biovation Limited
-
Patent number: 7125689Abstract: Protein, or parts of proteins, may be rendered non-immunogenic, or less immunogenic, to a given species by identifying in their amino acid sequences one or more potential epitopes for T-cells of the given species and modifying the amino acid sequence to eliminate at least one of the T-cell epitopes. This eliminates or reduces the immunogenicity of the protein when exposed to the immune system of the given species. Monoclonal antibodies and other immunoglobulin-like molecules can particularly benefit from being de-immunised in this way: for example, mouse-derived immunoglobulins can be de-immunised for human therapeutic use.Type: GrantFiled: November 20, 2002Date of Patent: October 24, 2006Assignee: Biovation LimitedInventors: Francis Joseph Carr, Fiona Suzanne Adair, Anita Anne Hamilton, Graham Carter
-
Publication number: 20060099216Abstract: Disclosed is a chimaeric polypeptide comprising: a binding portion having specific binding affinity for a eukaryotic target cell surface component and an effector portion comprising an amino acid sequence capable of exerting a biological effect; whereby binding of the polypeptide to the cell surface component induces internalisation of at least the effector portion so as to allow the amino acid sequence to exert its biological effect, together with a vaccine comprising the chimaeric polypeptide of the invention, and a method of modulating the immune response of a human or animal subject.Type: ApplicationFiled: September 27, 2005Publication date: May 11, 2006Applicant: Biovation LimitedInventors: Donald Nicholas Cardy, Frank Carr
-
Patent number: 6974699Abstract: A method of releasing an agent for example, a chemotherapeutic, under predetermined conditions by protecting the agent within a lipid structure such as a liposome, causing lipase activity to be constituted by combining two or more components, e.g., recombinant N- or C-terminal Clostridium perfringens alpha-toxin fragments, one of these components being conjugated to a targeting molecule e.g., an antibody which binds to a target such as a tumor antigen. The lipid structure is then exposed to the constituted lipase activity such as to release the agent. Also disclosed are materials and kits for use in the method.Type: GrantFiled: November 21, 2001Date of Patent: December 13, 2005Assignee: Biovation LimitedInventors: Richard W Titball, Francis J Carr
-
Patent number: 6927025Abstract: This invention provides methods of protein/polypeptide screening based on the provision of libraries of individual proteins/polypeptides, which in turn can be screened for a number of activities, including cell binding and biological activity. Methods for recovering genes encoding such proteins/polypeptides are also provided.Type: GrantFiled: March 3, 2000Date of Patent: August 9, 2005Assignee: Biovation LimitedInventors: Francis Joseph Carr, Graham Carter, Anita Anne Hamilton, Fiona Suzanne Adair, Stephen Williams
-
Publication number: 20030153043Abstract: Protein, or parts of proteins, may be rendered non-immunogenic, or less immunogenic, to a given species by identifying in their amino acid sequences one or more potential epitopes for T-cells of the given species and modifying the amino acid sequence to eliminate at least one of the T-cell epitopes. This eliminates or reduces the immunogenicity of the protein when exposed to the immune system of the given species. Monoclonal antibodies and other immunoglobulin-like molecules can particularly benefit from being de-immunised in this way: for example, mouse-derived immunoglobulins can be de-immunised for human therapeutic use.Type: ApplicationFiled: November 20, 2002Publication date: August 14, 2003Applicant: Biovation LimitedInventors: Francis Joseph Carr, Fiona Suzanne Adair, Anita Anne Hamilton, Graham Carter
-
Patent number: 6472365Abstract: A method of releasing an agent for example, a chemotherapeutic, under predetermined conditions by protecting the agent within a lipid structure such as a liposome, causing lipase activity to be constituted by combining two or more components, e.g., recombinant N- or C-terminal Clostridium perfringens alpha-toxin fragments, one of these components being conjugated to a targeting molecule e.g., an antibody which binds to a target such as a tumor antigen. The lipid structure is then exposed to the constituted lipase activity such as to release the agent. Also disclose are materials and kits for use in the method.Type: GrantFiled: March 16, 1998Date of Patent: October 29, 2002Assignee: Biovation LimitedInventors: Richard W Titball, Francis J Carr